LAPSE:2023.2071
Published Article

LAPSE:2023.2071
Bergenin from Bergenia Species Produces a Protective Response against Myocardial Infarction in Rats
February 21, 2023
Abstract
Bergenin is a phenolic glycoside that has been reported to occur naturally in several plant species, reported as a cardioprotective. However, bergenin, one of the important phytochemicals in these plants, is still not reported as a cardioprotective. The present study was designed to investigate the cardioprotective effects of bergenin on isoproterenol-induced myocardial infarction in rats. Bergenin and atenolol were administered through intraperitoneal (i.p.) injection to Sprague Dawley (SD) rats in separate experiments for five (5) days. At the end of this period, rats were administered isoproterenol (80 mg/kg s.c.) to induce myocardial injury. After induction, rats were anaesthetized to record lead II ECG, then sacrificed, blood was collected to analyze cardiac marker enzymes, and a histopathological study of the heart tissues was also performed. Pretreatment with bergenin showed a significant decrease in ST-segment elevation, deep Q-wave, infarct size, and also normalized cardiac marker enzymes (cTnI, CPK, CK-MB, LDH, ALT, and AST), particularly at 3 mg/kg, as compared to isoproterenol treated group. Our findings revealed, for the first time, the use of glycoside bergenin as a potential cardioprotective agent against the isoproterenol-induced MI in rats.
Bergenin is a phenolic glycoside that has been reported to occur naturally in several plant species, reported as a cardioprotective. However, bergenin, one of the important phytochemicals in these plants, is still not reported as a cardioprotective. The present study was designed to investigate the cardioprotective effects of bergenin on isoproterenol-induced myocardial infarction in rats. Bergenin and atenolol were administered through intraperitoneal (i.p.) injection to Sprague Dawley (SD) rats in separate experiments for five (5) days. At the end of this period, rats were administered isoproterenol (80 mg/kg s.c.) to induce myocardial injury. After induction, rats were anaesthetized to record lead II ECG, then sacrificed, blood was collected to analyze cardiac marker enzymes, and a histopathological study of the heart tissues was also performed. Pretreatment with bergenin showed a significant decrease in ST-segment elevation, deep Q-wave, infarct size, and also normalized cardiac marker enzymes (cTnI, CPK, CK-MB, LDH, ALT, and AST), particularly at 3 mg/kg, as compared to isoproterenol treated group. Our findings revealed, for the first time, the use of glycoside bergenin as a potential cardioprotective agent against the isoproterenol-induced MI in rats.
Record ID
Keywords
bergenin, cardiac biomarker, ECG, histopathological, isoproterenol, myocardial infarction (MI)
Subject
Suggested Citation
Ahmad T, Haq IU, Khan T, Mahnashi MH, Alasmary MY, Almedhesh SA, Shehri HA, Alshahrani MA, Shah AJ. Bergenin from Bergenia Species Produces a Protective Response against Myocardial Infarction in Rats. (2023). LAPSE:2023.2071
Author Affiliations
Ahmad T: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, University Road, Abbottabad 22060, KPK, Pakistan; Department of Pharmacology, College of Pharmacy, University of Sargodha, University Road, Sargodha 40100, Punjab, Pakistan
Haq IU: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, University Road, Abbottabad 22060, KPK, Pakistan
Khan T: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, University Road, Abbottabad 22060, KPK, Pakistan
Mahnashi MH: Department of Pharmaceutical Chemistry, College of Pharmacy, Najran University, Najran 61441, Saudi Arabia
Alasmary MY: Medical Department, College of Medicine, Najran University, Najran 61441, Saudi Arabia [ORCID]
Almedhesh SA: Pediatric Department, College of Medicine, Najran University, Najran 61441, Saudi Arabia
Shehri HA: Medical Department, College of Medicine, Najran University, Najran 61441, Saudi Arabia [ORCID]
Alshahrani MA: Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, P.O. Box 1988, Najran 61441, Saudi Arabia
Shah AJ: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, University Road, Abbottabad 22060, KPK, Pakistan
Haq IU: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, University Road, Abbottabad 22060, KPK, Pakistan
Khan T: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, University Road, Abbottabad 22060, KPK, Pakistan
Mahnashi MH: Department of Pharmaceutical Chemistry, College of Pharmacy, Najran University, Najran 61441, Saudi Arabia
Alasmary MY: Medical Department, College of Medicine, Najran University, Najran 61441, Saudi Arabia [ORCID]
Almedhesh SA: Pediatric Department, College of Medicine, Najran University, Najran 61441, Saudi Arabia
Shehri HA: Medical Department, College of Medicine, Najran University, Najran 61441, Saudi Arabia [ORCID]
Alshahrani MA: Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, P.O. Box 1988, Najran 61441, Saudi Arabia
Shah AJ: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, University Road, Abbottabad 22060, KPK, Pakistan
Journal Name
Processes
Volume
10
Issue
7
First Page
1403
Year
2022
Publication Date
2022-07-19
ISSN
2227-9717
Version Comments
Original Submission
Other Meta
PII: pr10071403, Publication Type: Journal Article
Record Map
Published Article

LAPSE:2023.2071
This Record
External Link

https://doi.org/10.3390/pr10071403
Publisher Version
Download
Meta
Record Statistics
Record Views
274
Version History
[v1] (Original Submission)
Feb 21, 2023
Verified by curator on
Feb 21, 2023
This Version Number
v1
Citations
Most Recent
This Version
URL Here
https://psecommunity.org/LAPSE:2023.2071
Record Owner
Auto Uploader for LAPSE
Links to Related Works
[0.22 s]
